{"id":"https://openalex.org/W2033585196","doi":"https://doi.org/10.1111/j.1365-2141.2012.09173.x","title":"Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study","display_name":"Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study","alternate_titles":[],"publication_year":2012,"publication_date":"2012-05-29","ids":{"openalex":"https://openalex.org/W2033585196","doi":"https://doi.org/10.1111/j.1365-2141.2012.09173.x","mag":"2033585196","pmid":"https://pubmed.ncbi.nlm.nih.gov/22640031"},"language":"en","primary_location":{"id":"doi:10.1111/j.1365-2141.2012.09173.x","doi":"https://doi.org/10.1111/j.1365-2141.2012.09173.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1365-2141.2012.09173.x","pdf_url":null,"source":{"id":"https://openalex.org/S153015021","display_name":"British Journal of Haematology","issn_l":"0007-1048","issn":["0007-1048","1365-2141"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Haematology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2033585196"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"http://www.ecog.org/cite/E4A03DOC20080806.PDF","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5057911528","display_name":"Andrzej J. Jakubowiak","orcid":"https://orcid.org/0000-0002-2597-6822","observed_orcids":["https://orcid.org/0000-0002-2597-6822"]},"institutions":[{"id":"https://openalex.org/I4210087865","display_name":"University of Chicago Medical Center","ror":"https://ror.org/0076kfe04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087865"]},{"id":"https://openalex.org/I4390039285","display_name":"U-M Rogel Cancer Center","ror":"https://ror.org/05asdy483","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210114445","https://openalex.org/I4390039285"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Andrzej J. Jakubowiak","raw_affiliation_strings":["University of Chicago Medical Center Chicago IL USA","University of Michigan Cancer Center, Ann Arbor, MI, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Chicago Medical Center Chicago IL USA","institution_ids":["https://openalex.org/I4210087865"]},{"raw_affiliation_string":"University of Michigan Cancer Center, Ann Arbor, MI, USA","institution_ids":["https://openalex.org/I4390039285"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043526996","display_name":"Paul Gerard Guy Richardson","orcid":"https://orcid.org/0000-0002-7426-8865","observed_orcids":["https://orcid.org/0000-0002-7426-8865"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Paul G. Richardson","raw_affiliation_strings":["Dana Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111920307","display_name":"Todd M. Zimmerman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]},{"id":"https://openalex.org/I4390039251","display_name":"University of Chicago Medicine Comprehensive Cancer Center","ror":"https://ror.org/042wftp98","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087865","https://openalex.org/I4390039251"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Todd Zimmerman","raw_affiliation_strings":["University of Chicago Cancer Center Chicago IL USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Chicago Cancer Center Chicago IL USA","institution_ids":["https://openalex.org/I40347166","https://openalex.org/I4390039251"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087799564","display_name":"Melissa Alsina","orcid":"https://orcid.org/0000-0003-4946-823X","observed_orcids":["https://orcid.org/0000-0003-4946-823X"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Melissa Alsina","raw_affiliation_strings":["H. Lee Moffitt Cancer Center Tampa FL USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H. Lee Moffitt Cancer Center Tampa FL USA","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077897003","display_name":"Jonathan L. Kaufman","orcid":"https://orcid.org/0000-0002-5687-6429","observed_orcids":["https://orcid.org/0000-0002-5687-6429"]},"institutions":[{"id":"https://openalex.org/I4390039307","display_name":"Winship Cancer Institute","ror":"https://ror.org/02gars961","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I132943300","https://openalex.org/I150468666","https://openalex.org/I4390039307"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jonathan L. Kaufman","raw_affiliation_strings":["Winship Cancer Institute of Emory University, Atlanta, GA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Winship Cancer Institute of Emory University, Atlanta, GA, USA","institution_ids":["https://openalex.org/I4390039307"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049726842","display_name":"Malathi Kandarpa","orcid":"https://orcid.org/0000-0002-0440-4964","observed_orcids":["https://orcid.org/0000-0002-0440-4964"]},"institutions":[{"id":"https://openalex.org/I4390039285","display_name":"U-M Rogel Cancer Center","ror":"https://ror.org/05asdy483","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210114445","https://openalex.org/I4390039285"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Malathi Kandarpa","raw_affiliation_strings":["University of Michigan Cancer Center Ann Arbor MI USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Michigan Cancer Center Ann Arbor MI USA","institution_ids":["https://openalex.org/I4390039285"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077499227","display_name":"Stephanie J. Kraftson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4390039285","display_name":"U-M Rogel Cancer Center","ror":"https://ror.org/05asdy483","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210114445","https://openalex.org/I4390039285"]},{"id":"https://openalex.org/I87216513","display_name":"Michigan State University","ror":"https://ror.org/05hs6h993","country_code":"US","type":"education","lineage":["https://openalex.org/I87216513"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Stephanie Kraftson","raw_affiliation_strings":["Michigan State University East Lansing MI USA","University of Michigan Cancer Center, Ann Arbor, MI, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Michigan State University East Lansing MI USA","institution_ids":["https://openalex.org/I87216513"]},{"raw_affiliation_string":"University of Michigan Cancer Center, Ann Arbor, MI, USA","institution_ids":["https://openalex.org/I4390039285"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110477798","display_name":"Charles Warren Ross","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I27837315","display_name":"University of Michigan","ror":"https://ror.org/00jmfr291","country_code":"US","type":"education","lineage":["https://openalex.org/I27837315"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Charles W. Ross","raw_affiliation_strings":["Department of Pathology; University of Michigan; Ann Arbor; MI; USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pathology; University of Michigan; Ann Arbor; MI; USA","institution_ids":["https://openalex.org/I27837315"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Colleen Harvey","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4390039285","display_name":"U-M Rogel Cancer Center","ror":"https://ror.org/05asdy483","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210114445","https://openalex.org/I4390039285"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Colleen Harvey","raw_affiliation_strings":["University of Michigan Cancer Center Ann Arbor MI USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Michigan Cancer Center Ann Arbor MI USA","institution_ids":["https://openalex.org/I4390039285"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091207345","display_name":"Teru Hideshima","orcid":"https://orcid.org/0000-0003-2939-6224","observed_orcids":["https://orcid.org/0000-0003-2939-6224"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Teru Hideshima","raw_affiliation_strings":["Dana Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074058246","display_name":"Peter Sportelli","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Peter Sportelli","raw_affiliation_strings":["Keryx Biopharmaceuticals Inc New York NY USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Keryx Biopharmaceuticals Inc New York NY USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091239941","display_name":"Enrique Poradosu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Enrique Poradosu","raw_affiliation_strings":["Keryx Biopharmaceuticals Inc New York NY USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Keryx Biopharmaceuticals Inc New York NY USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103462621","display_name":"Lesa R. Gardner","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Lesa Gardner","raw_affiliation_strings":["Keryx Biopharmaceuticals Inc New York NY USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Keryx Biopharmaceuticals Inc New York NY USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023135961","display_name":"Kathy E. Giusti","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Kathy Giusti","raw_affiliation_strings":["Multiple Myeloma Research Consortium Norwalk CT USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Multiple Myeloma Research Consortium Norwalk CT USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5032464400","display_name":"Kenneth Carl Anderson","orcid":"https://orcid.org/0000-0002-6418-0886","observed_orcids":["https://orcid.org/0000-0002-6418-0886"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Kenneth C. Anderson","raw_affiliation_strings":["Dana Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":9,"corresponding_author_ids":["https://openalex.org/A5057911528"],"corresponding_institution_ids":["https://openalex.org/I4210087865","https://openalex.org/I4390039285"],"apc_list":{"value":5190,"currency":"USD","value_usd":5190},"apc_paid":null,"fwci":5.4347,"has_fulltext":true,"cited_by_count":68,"citation_normalized_percentile":{"value":0.96358661,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":87,"max":100},"biblio":{"volume":"158","issue":"4","first_page":"472","last_page":"480"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11221","display_name":"Bone health and treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/perifosine","display_name":"perifosine","score":0.9610000252723694},{"id":"https://openalex.org/keywords/lenalidomide","display_name":"lenalidomide","score":1.0},{"id":"https://openalex.org/keywords/dexamethasone","display_name":"dexamethasone","score":1.0},{"id":"https://openalex.org/keywords/relapsed-refractory-multiple-myeloma","display_name":"relapsed/refractory multiple myeloma","score":0.8939999938011169},{"id":"https://openalex.org/keywords/akt-inhibitors","display_name":"AKT inhibitors","score":0.7699999809265137},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6290000081062317},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.8709999918937683},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.781000018119812},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8040000200271606},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.5040000081062317}],"concepts":[{"id":"https://openalex.org/C2776063141","wikidata":"https://www.wikidata.org/wiki/Q425681","display_name":"Lenalidomide","level":3,"score":0.9444683194160461},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8390108346939087},{"id":"https://openalex.org/C2780401358","wikidata":"https://www.wikidata.org/wiki/Q422252","display_name":"Dexamethasone","level":2,"score":0.7956525087356567},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.7570856809616089},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.7387542724609375},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6175448298454285},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.609038770198822},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4916275143623352},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.4717821776866913},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4342101216316223},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4241599440574646},{"id":"https://openalex.org/C2778850193","wikidata":"https://www.wikidata.org/wiki/Q3775974","display_name":"Febrile neutropenia","level":4,"score":0.4191463589668274},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3464668095111847},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3462182879447937},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.24253398180007935},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.22333469986915588},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000077269","descriptor_name":"Lenalidomide","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003907","descriptor_name":"Dexamethasone","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003907","descriptor_name":"Dexamethasone","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D010767","descriptor_name":"Phosphorylcholine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D010767","descriptor_name":"Phosphorylcholine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D010767","descriptor_name":"Phosphorylcholine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D012008","descriptor_name":"Recurrence","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013792","descriptor_name":"Thalidomide","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D013792","descriptor_name":"Thalidomide","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D013792","descriptor_name":"Thalidomide","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051057","descriptor_name":"Proto-Oncogene Proteins c-akt","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D053208","descriptor_name":"Kaplan-Meier Estimate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058539","descriptor_name":"Phosphatidylinositol 3-Kinase","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1111/j.1365-2141.2012.09173.x","doi":"https://doi.org/10.1111/j.1365-2141.2012.09173.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1365-2141.2012.09173.x","pdf_url":null,"source":{"id":"https://openalex.org/S153015021","display_name":"British Journal of Haematology","issn_l":"0007-1048","issn":["0007-1048","1365-2141"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Haematology","raw_type":"journal-article"},{"id":"pmid:22640031","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/22640031","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British journal of haematology","raw_type":"Clinical Trial, Phase I"},{"id":"pmh:oai:deepblue.lib.umich.edu:2027.42/92443","doi":null,"is_oa":true,"landing_page_url":"https://hdl.handle.net/2027.42/92443","pdf_url":"http://www.ecog.org/cite/E4A03DOC20080806.PDF","source":{"id":"https://openalex.org/S4306400393","display_name":"Deep Blue (University of Michigan)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I27837315","host_organization_name":"University of Michigan","host_organization_lineage":["https://openalex.org/I27837315"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Article"},{"id":"pmh:oai:CiteSeerX.psu:10.1.1.910.2257","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.910.2257","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"https://deepblue.lib.umich.edu/bitstream/handle/2027.42/92443/bjh9173.pdf%3Bjsessionid%3D5B7FABC6AFA2BC09553D17C12B1ADCA1?sequence%3D1","raw_type":"text"}],"best_oa_location":{"id":"pmh:oai:deepblue.lib.umich.edu:2027.42/92443","doi":null,"is_oa":true,"landing_page_url":"https://hdl.handle.net/2027.42/92443","pdf_url":"http://www.ecog.org/cite/E4A03DOC20080806.PDF","source":{"id":"https://openalex.org/S4306400393","display_name":"Deep Blue (University of Michigan)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I27837315","host_organization_name":"University of Michigan","host_organization_lineage":["https://openalex.org/I27837315"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2033585196.pdf","grobid_xml":"https://content.openalex.org/works/W2033585196.grobid-xml"},"referenced_works_count":30,"referenced_works":["https://openalex.org/W1539095566","https://openalex.org/W1971336819","https://openalex.org/W1974798389","https://openalex.org/W1978377409","https://openalex.org/W1986625550","https://openalex.org/W1992538067","https://openalex.org/W1993272300","https://openalex.org/W2007998678","https://openalex.org/W2021954218","https://openalex.org/W2039217634","https://openalex.org/W2044436186","https://openalex.org/W2063827408","https://openalex.org/W2066800926","https://openalex.org/W2099110265","https://openalex.org/W2100890240","https://openalex.org/W2104028456","https://openalex.org/W2124560610","https://openalex.org/W2127760782","https://openalex.org/W2137941402","https://openalex.org/W2144724291","https://openalex.org/W2147769421","https://openalex.org/W2169336006","https://openalex.org/W2497721881","https://openalex.org/W2533666715","https://openalex.org/W2536202623","https://openalex.org/W2564975161","https://openalex.org/W2592101711","https://openalex.org/W2593730936","https://openalex.org/W2979869133","https://openalex.org/W2979916566"],"related_works":["https://openalex.org/W2979736044","https://openalex.org/W2592101711","https://openalex.org/W3014488763","https://openalex.org/W2551916165","https://openalex.org/W2137941402","https://openalex.org/W2558393839","https://openalex.org/W2593730936","https://openalex.org/W2564975161","https://openalex.org/W2981550333","https://openalex.org/W2533666715"],"abstract_inverted_index":{"The":[0,100],"combination":[1],"of":[2,45,56,70],"lenalidomide-dexamethasone":[3],"is":[4],"active":[5],"in":[6,47,166,178],"multiple":[7],"myeloma":[8],"(MM).":[9],"Preclinical":[10],"data":[11],"showed":[12],"that":[13],"the":[14,26,37,41],"Akt":[15],"inhibitor,":[16],"perifosine,":[17],"sensitized":[18],"MM":[19],"cells":[20],"to":[21,35],"lenalidomide":[22,62],"and":[23,39,49,61,111,114,123,155,173,180],"dexamethasone,":[24],"providing":[25],"rationale":[27],"for":[28,98],"this":[29],"Phase":[30],"I,":[31],"multicentre,":[32],"single-arm":[33],"study":[34],"assess":[36],"safety":[38],"determine":[40],"maximum-tolerated":[42],"dose":[43,88],"(MTD)":[44],"perifosine-lenalidomide-dexamethasone":[46],"relapsed":[48,179],"relapsed/refractory":[50,181],"MM.":[51,182],"Patients":[52],"received":[53],"escalating":[54],"doses":[55],"perifosine":[57],"50-100":[58],"mg":[59,64,77],"daily":[60,66],"15-25":[63],"once":[65],"on":[67],"days":[68],"1-21":[69],"each":[71],"28-d":[72],"cycle,":[73],"plus":[74],"dexamethasone":[75],"20-40":[76],"weekly":[78],"thereafter,":[79],"as":[80],"indicated.":[81],"Thirty-two":[82],"patients":[83,96],"were":[84,108],"enrolled":[85],"across":[86],"four":[87],"cohorts.":[89],"MTD":[90],"was":[91,152,162,170],"not":[92],"reached,":[93],"with":[94,143,164],"31":[95],"evaluable":[97,128],"safety/tolerability.":[99],"most":[101],"common":[102],"all-causality":[103],"grade":[104,115],"1-2":[105],"adverse":[106],"events":[107],"fatigue":[109],"(48%)":[110],"diarrhoea":[112],"(45%),":[113],"3-4":[116],"neutropenia":[117],"(26%),":[118],"hypophosphataemia":[119],"(23%),":[120],"thrombocytopenia":[121],"(16%),":[122],"leucopenia":[124],"(13%).":[125],"Among":[126],"30":[127],"patients,":[129],"73%":[130],"(95%":[131],"confidence":[132],"interval,":[133],"57\u00b75-89\u00b72%)":[134],"achieved":[135],"a":[136,144],"minimal":[137],"response":[138,146],"or":[139,147],"better,":[140],"including":[141],"50%":[142],"partial":[145],"better.":[148],"Median":[149],"progression-free":[150],"survival":[151,158],"10\u00b78":[153],"months":[154],"median":[156],"overall":[157],"30\u00b76":[159],"months.":[160],"Response":[161],"associated":[163],"phospho-Akt":[165],"pharmacodynamic":[167],"studies.":[168],"Perifosine-lenalidomide-dexamethasone":[169],"well":[171],"tolerated":[172],"demonstrated":[174],"encouraging":[175],"clinical":[176],"activity":[177]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2033585196","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":6},{"year":2020,"cited_by_count":7},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":6},{"year":2016,"cited_by_count":7},{"year":2015,"cited_by_count":7},{"year":2014,"cited_by_count":6},{"year":2013,"cited_by_count":16},{"year":2012,"cited_by_count":2}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
